TY  - CHAP
M1  - Book, Section
TI  - HIV Infection & AIDS: Treatment
A1  - Katz, Mitchell H.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - KEY  CLINICAL  UPDATES  IN  HIV  INFECTION  &  AIDS:  TREATMENTCabotegravir  is  an  integrase  inhibitor  that  has  been  approved  for  use  in  the  United  States,  Canada,  and  in  the  European  Union.It  is  intended  to  be  given  with  rilpivirine.  The  advantage  of  this  combination  is  that  it  is  complete  therapy  for  patients  in  whom  the  viral  load  is  stable  and  suppressed  (<  50  copies)  on  their  current  regimen,  which  is  then  stopped  in  favor  of  cabotegravir/rilpivirine.Fostemsavir,  an  attachment  inhibitor,  and  ibalizumab,  a  monoclonal  antibody,  are  FDA  approved  specifically  for  heavily  treated  adults  with  multidrug-resistant  HIV  who  are  not  responding  to  their  existing  regimen.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184165539
ER  -